J Cancer 2019; 10(12):2670-2678. doi:10.7150/jca.32072 This issue

Research Paper

SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer

Hao Li1,2,3,4, Shi-Rong Zhang1,2,3,4, Hua-Xiang Xu1,2,3,4, Wen-Quan Wang1,2,3,4, Shuo Li1,2,3,4, Tian-Jiao Li1,2,3,4, Quan-Xing Ni1,2,3,4, Xian-Jun Yu1,2,3,4✉, Liang Liu1,2,3,4✉, Chun-Tao Wu1,2,3,4✉

1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 20032, China.
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
3. Shanghai Pancreatic Cancer Institute, Shanghai 200032, China.
4. Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China.
Hao Li and Shi-Rong Zhang contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Li H, Zhang SR, Xu HX, Wang WQ, Li S, Li TJ, Ni QX, Yu XJ, Liu L, Wu CT. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. J Cancer 2019; 10(12):2670-2678. doi:10.7150/jca.32072. Available from https://www.jcancer.org/v10p2670.htm

File import instruction


Introduction: SRPX2 and RAB31 play important roles in tumorigenesis and metastasis; however, their prognostic value in pancreatic cancer remains unclear. This study aimed to investigate the potential interactions and effects of SRPX2 and RAB31 on the diagnosis and prognosis of pancreatic cancer.

Methods: The expression of SRPX2 and RAB31 in pancreatic tumor tissues and cells was evaluated through database mining of the Oncomine, Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and validated the results through immunohistochemistry (IHC) and Western blot in our clinical database. Protein-protein interactions were explored by immunofluorescence and Co-immunoprecipitation (Co-IP). Two hundred tissue microarray specimens from patients (79 training and 121 validation), who underwent curative pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) were used. Additionally, the association between the SRPX2 and RAB31 and prognosis of PDAC patients after surgery was analyzed.

Results: The expression of SRPX2 and RAB31 was highly increased in pancreatic cancer, and there was a significant positive correlation between these two proteins. Co-IP showed the direct interaction between SRPX2 and RAB31. Kaplan-Meier analysis showed that positive expression of SRPX2 and RAB31 was associated with reduced disease-free survival (DFS) and overall survival (OS) of PDAC patients in the training set and the validation sets. Furthermore, multivariate analysis indicated that the 8th edition TNM stage and combination of SRPX2 and RAB31 were independent prognostic factors that associated with OS and DFS in the training, and the validation sets, respectively.

Conclusions: The combination of SRPX2 and RAB31 can be important markers for the prognosis of pancreatic cancer.

Keywords: Pancreatic ductal adenocarcinoma, SRPX2, RAB31, Prognosis